Skip to Main Content

John Maraganore’s decision to step down as Alnylam Pharmaceuticals’ CEO after almost 20 years came as a shock to people outside of the company — enough to send the company’s stock tumbling by more than 16% that day.

But it was a shock, too, to people within Alnylam, Maraganore recalled at the 2021 STAT Summit in Boston on Tuesday. Including, even, his successor as CEO, Yvonne Greenstreet.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

Create a display name to comment

This name will appear with your comment